Tag Archives: ZALTRAP

Memorial Sloan-Kettering Will Not Offer Zaltrap

Memorial Sloan-Kettering Cancer Center made a very public announcement—and explanation—today in a New York Times op-ed about why they will not offer the new drug Zaltrap® (ziv-aflibercept) to its metastatic colorectal cancer patients. The authors, all world-renowned cancer specialists at the world’s oldest cancer center, in an op-ed headlined “In Cancer Care, Cost Matters,” essentially challenged other cancer centers to take action where politicians fear to tread. “We recently made a decision that should have been a no-brainer,” wrote Drs. Peter B. Bach, Leonard B. Saltz and Robert E. Wittes. “The drug, Zaltrap, has proved to be no better than a similar medicine we already have for advanced colorectal cancer, while its price—at

Ziv-Aflibercept gets FDA approval

Ziv-Aflibercept Approved as 2nd line treatment for metastatic CRC   For the first time in more than five years, the FDA has approved a new drug for certain patients who have metastatic colorectal cancer. The FDA has approved ZALTRAP® (ziv-aflibercept) to be used with FOLFIRI as a “second-line” treatment for patients with stage IV colorectal cancer whose cancer got worse despite an initial oxaliplatin-based treatment (e.g. FOLFOX). 

Positive News for VEGF Trap in Colorectal Cancer

ZALTRAP® (aflibercept) added to survival time when given along with FOLFIRI to colorectal cancer patients who had already progressed on earlier oxaliplatin treatment. On April 26, 2011, sanofi-aventis and Regeneron Pharmaceuticals announced positive results for the Phase III VELOUR trial, which compared ZALTRAP to a placebo during FOLFIRI chemotherapy. Detailed results will be available at an upcoming medical conference.

Top